+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Antidiabetic Drugs Market by Type, Disease, Patient - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 184 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5264372
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Antidiabetic Drugs Market grew from USD 46.93 billion in 2023 to USD 51.42 billion in 2024. It is expected to continue growing at a CAGR of 10.14%, reaching USD 92.32 billion by 2030.

The scope of the antidiabetic drugs market encompasses pharmaceuticals used in managing diabetes mellitus, a chronic disease characterized by high blood sugar levels. The market is defined by various drug classes, including insulin, biguanides, SGLT2 inhibitors, DPP-4 inhibitors, and GLP-1 receptor agonists, among others. The necessity for these medications arises from the global increase in diabetes prevalence due to lifestyle changes, aging populations, and rising obesity rates. Applications primarily focus on glycemic control to prevent complications such as cardiovascular diseases and neuropathies. End-users include hospitals, pharmacies, and diabetic care centers. Growth is influenced by factors such as technological advancements in drug delivery systems, increased R&D investments, and rising awareness of diabetes management. Latest opportunities lie in developing personalized medicine approaches, utilizing AI for patient monitoring, and expanding access in emerging markets. Recommendations include investing in novel drug classes and exploring combination therapies to improve efficacy and patient compliance. However, market growth is challenged by stringent regulatory requirements, high drug development costs, and patent expirations, leading to generic competition. Moreover, the complexity of diabetes as a disease presents challenges in creating universal treatment solutions. Innovation should focus on non-invasive glucose monitoring technologies and exploring natural compounds that can offer safer treatment alternatives. The market is characterized by high competition among pharmaceutical giants, with a significant focus on clinical trial outcomes to drive approval and adoption rates. Prospective areas for business growth include partnerships for model-based drug design and emphasis on patient education programs to promote lifestyle interventions alongside medication adherence. In conclusion, the antidiabetic drugs market is dynamic, with opportunities awaiting those ready to innovate and navigate regulatory landscapes strategically.

Understanding Market Dynamics in the Antidiabetic Drugs Market

The Antidiabetic Drugs Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Rising prevalence of diabetes and increasing obesity among people
    • Growing awareness among patients and healthcare professionals regarding the importance of diabetes management
    • Initiatives and programs supporting diabetes awareness & treatment
  • Market Restraints
    • Adverse effects associated with antidiabetic drugs
  • Market Opportunities
    • Ongoing research and development for new antidiabetic drugs
    • Governments and private companies collaborations to supply inexpensive drugs
  • Market Challenges
    • Stringent regulatory requirements for the approval of antidiabetic drugs

Exploring Porter’s Five Forces for the Antidiabetic Drugs Market

Porter’s Five Forces framework further strengthens the insights of the Antidiabetic Drugs Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Antidiabetic Drugs Market

External macro-environmental factors deeply influence the performance of the Antidiabetic Drugs Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Antidiabetic Drugs Market

The Antidiabetic Drugs Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Antidiabetic Drugs Market

The Antidiabetic Drugs Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Antidiabetic Drugs Market

The Antidiabetic Drugs Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antidiabetic Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alkem Laboratories Ltd., Aristo Pharmaceuticals Pvt. Ltd., Astellas Pharma Inc., AstraZeneca PLC, Biocon Limited, Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Limited, Cipla Limited, Dr. Reddy's Laboratories, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Halozyme Therapeutics, Inc., Johnson & Johnson Services, Inc., Mankind Pharma Ltd., Merck KGaA, Novo Nordisk A/S, Oramed Pharmaceuticals Inc., Pfizer Inc., PHC Holdings Corporation, Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Tonghua Dongbao Pharmaceutical Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Antidiabetic Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Type
    • Alpha-Glucosidase Inhibitors
    • Biguanides
    • DPP-IV (Dipeptidyl Peptidase) Inhibitors
    • GLP-1 (Glucagon-like Peptide) Agonists
    • Insulin
      • Intermediate-Acting Insulin
      • Long-Acting Analog
      • Premixed Insulin
      • Rapid-Acting Analog
      • Short-Acting Analog
    • Meglitinides
    • SGLT-II (Sodium Glucose Transport Proteins) Inhibitors
    • Sulphonylureas
    • Thiazolidinedione
  • Disease
    • Diabetes Mellitus Type 1
    • Diabetes Mellitus Type 2
  • Patient
    • Adult
    • Geriatric
    • Pediatric
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of diabetes and increasing obesity among people
5.1.1.2. Growing awareness among patients and healthcare professionals regarding the importance of diabetes management
5.1.1.3. Initiatives and programs supporting diabetes awareness & treatment
5.1.2. Restraints
5.1.2.1. Adverse effects associated with antidiabetic drugs
5.1.3. Opportunities
5.1.3.1. Ongoing research and development for new antidiabetic drugs
5.1.3.2. Governments and private companies collaborations to supply inexpensive drugs
5.1.4. Challenges
5.1.4.1. Stringent regulatory requirements for the approval of antidiabetic drugs
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Antidiabetic Drugs Market, by Type
6.1. Introduction
6.2. Alpha-Glucosidase Inhibitors
6.3. Biguanides
6.4. DPP-IV (Dipeptidyl Peptidase) Inhibitors
6.5. GLP-1 (Glucagon-like Peptide) Agonists
6.6. Insulin
6.6.1. Intermediate-Acting Insulin
6.6.2. Long-Acting Analog
6.6.3. Premixed Insulin
6.6.4. Rapid-Acting Analog
6.6.5. Short-Acting Analog
6.7. Meglitinides
6.8. SGLT-II (Sodium Glucose Transport Proteins) Inhibitors
6.9. Sulphonylureas
6.10. Thiazolidinedione
7. Antidiabetic Drugs Market, by Disease
7.1. Introduction
7.2. Diabetes Mellitus Type 1
7.3. Diabetes Mellitus Type 2
8. Antidiabetic Drugs Market, by Patient
8.1. Introduction
8.2. Adult
8.3. Geriatric
8.4. Pediatric
9. Americas Antidiabetic Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Antidiabetic Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Antidiabetic Drugs Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. ANTIDIABETIC DRUGS MARKET RESEARCH PROCESS
FIGURE 2. ANTIDIABETIC DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2023 VS 2030 (%)
FIGURE 11. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 13. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 15. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ANTIDIABETIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 21. ANTIDIABETIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. ANTIDIABETIC DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. ANTIDIABETIC DRUGS MARKET DYNAMICS
TABLE 7. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ALPHA-GLUCOSIDASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY BIGUANIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY DPP-IV (DIPEPTIDYL PEPTIDASE) INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY GLP-1 (GLUCAGON-LIKE PEPTIDE) AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY INTERMEDIATE-ACTING INSULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY LONG-ACTING ANALOG, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY PREMIXED INSULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY RAPID-ACTING ANALOG, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY SHORT-ACTING ANALOG, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY MEGLITINIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY SGLT-II (SODIUM GLUCOSE TRANSPORT PROTEINS) INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY SULPHONYLUREAS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY THIAZOLIDINEDIONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY DIABETES MELLITUS TYPE 1, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY DIABETES MELLITUS TYPE 2, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 38. ARGENTINA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 39. BRAZIL ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 43. CANADA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 44. CANADA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 45. CANADA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 46. CANADA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 47. MEXICO ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 48. MEXICO ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 49. MEXICO ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 50. MEXICO ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 56. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 57. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 58. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 59. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 60. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 61. AUSTRALIA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 62. AUSTRALIA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 63. AUSTRALIA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 64. AUSTRALIA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 65. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 66. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 67. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 68. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 69. INDIA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 70. INDIA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 71. INDIA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 72. INDIA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 73. INDONESIA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 74. INDONESIA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 75. INDONESIA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 76. INDONESIA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 77. JAPAN ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 78. JAPAN ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 79. JAPAN ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 80. JAPAN ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 81. MALAYSIA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 82. MALAYSIA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 83. MALAYSIA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 84. MALAYSIA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 85. PHILIPPINES ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 86. PHILIPPINES ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 87. PHILIPPINES ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 88. PHILIPPINES ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 89. SINGAPORE ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 90. SINGAPORE ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 91. SINGAPORE ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 92. SINGAPORE ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 93. SOUTH KOREA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 94. SOUTH KOREA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 95. SOUTH KOREA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 96. SOUTH KOREA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 97. TAIWAN ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 98. TAIWAN ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 99. TAIWAN ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 100. TAIWAN ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 101. THAILAND ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 102. THAILAND ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 103. THAILAND ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 104. THAILAND ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 105. VIETNAM ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 106. VIETNAM ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 107. VIETNAM ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 108. VIETNAM ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 114. DENMARK ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 115. DENMARK ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 116. DENMARK ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 117. DENMARK ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 118. EGYPT ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 119. EGYPT ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 120. EGYPT ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 121. EGYPT ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 122. FINLAND ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 123. FINLAND ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 124. FINLAND ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 125. FINLAND ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 126. FRANCE ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 127. FRANCE ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 128. FRANCE ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 129. FRANCE ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 130. GERMANY ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 131. GERMANY ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 132. GERMANY ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 133. GERMANY ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 134. ISRAEL ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 135. ISRAEL ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 136. ISRAEL ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 137. ISRAEL ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 138. ITALY ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 139. ITALY ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 140. ITALY ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 141. ITALY ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 142. NETHERLANDS ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 143. NETHERLANDS ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 144. NETHERLANDS ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 145. NETHERLANDS ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 146. NIGERIA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 147. NIGERIA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 148. NIGERIA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 149. NIGERIA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 150. NORWAY ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 151. NORWAY ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 152. NORWAY ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 153. NORWAY ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 154. POLAND ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 155. POLAND ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 156. POLAND ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 157. POLAND ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 158. QATAR ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 159. QATAR ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 160. QATAR ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 161. QATAR ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 162. RUSSIA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 163. RUSSIA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 164. RUSSIA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 165. RUSSIA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 166. SAUDI ARABIA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 167. SAUDI ARABIA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 168. SAUDI ARABIA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 169. SAUDI ARABIA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 170. SOUTH AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 171. SOUTH AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 172. SOUTH AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 173. SOUTH AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 174. SPAIN ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 175. SPAIN ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 176. SPAIN ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 177. SPAIN ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 178. SWEDEN ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 179. SWEDEN ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 180. SWEDEN ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 181. SWEDEN ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 182. SWITZERLAND ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 183. SWITZERLAND ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 184. SWITZERLAND ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 185. SWITZERLAND ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 186. TURKEY ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 187. TURKEY ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 188. TURKEY ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 189. TURKEY ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 190. UNITED ARAB EMIRATES ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 191. UNITED ARAB EMIRATES ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 192. UNITED ARAB EMIRATES ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 193. UNITED ARAB EMIRATES ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 194. UNITED KINGDOM ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 196. UNITED KINGDOM ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
TABLE 198. ANTIDIABETIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 199. ANTIDIABETIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Antidiabetic Drugs Market, which are profiled in this report, include:
  • Abbott Laboratories
  • Alkem Laboratories Ltd.
  • Aristo Pharmaceuticals Pvt. Ltd.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Biocon Limited
  • Boehringer Ingelheim International GmbH
  • Cadila Pharmaceuticals Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Ltd.
  • Halozyme Therapeutics, Inc.
  • Johnson & Johnson Services, Inc.
  • Mankind Pharma Ltd.
  • Merck KGaA
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Pfizer Inc.
  • PHC Holdings Corporation
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Tonghua Dongbao Pharmaceutical Co., Ltd.

Methodology

Loading
LOADING...

Table Information